140 related articles for article (PubMed ID: 35246972)
1. Spurious results for total and free prostate-specific antigen (PSA); sometimes really "a riddle wrapped in a mystery inside an enigma".
Dorizzi RM; Maltoni P; Sgarzani C; Torello M; Montanari F
Clin Chem Lab Med; 2022 Apr; 60(5):e91-e94. PubMed ID: 35246972
[No Abstract] [Full Text] [Related]
2. Reply to: Spurious results for total and free prostate-specific antigen (PSA); sometimes really "a riddle wrapped in a mystery inside an enigma".
Ferraro S; Biganzoli EM; Plebani M
Clin Chem Lab Med; 2022 Apr; 60(5):e95-e96. PubMed ID: 35258238
[No Abstract] [Full Text] [Related]
3. Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used?
Lein M; Stephan C; Jung K; Schnorr D; Loening S
Cancer Invest; 1998; 16(1):45-9. PubMed ID: 9474251
[TBL] [Abstract][Full Text] [Related]
4. Bone metastases from prostate cancer without elevated prostate-specific antigen levels: diagnosis by anti-PSA immunostaining.
Berthelot JM; Gouin F; Denis M; Nomballais MF; Maugars Y; Blaive-Cervi S; Prost A
Rev Rhum Engl Ed; 1995 Jan; 62(1):54-5. PubMed ID: 7540487
[No Abstract] [Full Text] [Related]
5. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
6. [Immuno-analytical characteristics of PSA and derived biomarkers (total PSA, free PSA, p2PSA)].
Desbène C; Boissan M; Loric S; Lamy PJ; Piéroni L
Ann Biol Clin (Paris); 2023 Mar; 81(1):7-23. PubMed ID: 36757372
[TBL] [Abstract][Full Text] [Related]
7. [The percentage of free prostate specific antigen used in detecting prostate cancer].
Yang L; Fang Z; Song J; Deng S
Zhonghua Wai Ke Za Zhi; 1999 Jan; 37(1):47-9. PubMed ID: 11829778
[TBL] [Abstract][Full Text] [Related]
8. Molecular forms of serum prostate-specific antigen: the clinical usefulness of percent free PSA to discriminate prostate cancer from BPH.
Abrahamsson PA; Kuriyama M
Hinyokika Kiyo; 1998 Apr; 44(4):223-32. PubMed ID: 9617617
[TBL] [Abstract][Full Text] [Related]
9. Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies?
Prestigiacomo AF; Stamey TA
J Urol; 1997 Jan; 157(1):189-94. PubMed ID: 8976248
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of free PSA/total PSA (prostate-specific antigen) ratio in the diagnosis of prostate cancer.
Filella X; Alcover J; Molina R; Rodríguez A; Carretero P; Ballesta AM
Eur J Cancer; 1997 Jul; 33(8):1226-9. PubMed ID: 9301447
[TBL] [Abstract][Full Text] [Related]
11. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
Wymenga LF; Mensink HJ
Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
[TBL] [Abstract][Full Text] [Related]
12. Diagnosing prostate cancer at a curable stage means providing PSA tests to asymptomatic patients.
Booth CM; Chinegwundoh F; Allen S; Van Poppel H
BMJ; 2022 Jul; 378():o1714. PubMed ID: 35820680
[No Abstract] [Full Text] [Related]
13. A prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer.
Mitchell ID; Croal BL; Dickie A; Cohen NP; Ross I
J Urol; 2001 May; 165(5):1549-53. PubMed ID: 11342915
[TBL] [Abstract][Full Text] [Related]
14. The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer.
Partin AW; Carter HB
Urol Clin North Am; 1996 Nov; 23(4):531-40. PubMed ID: 8948408
[TBL] [Abstract][Full Text] [Related]
15. Complexed prostate-specific antigen improvement in detecting prostate cancer.
Okihara K; Babaian RJ
Curr Urol Rep; 2001 Jun; 2(3):253-8. PubMed ID: 12084274
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen: current status.
Brawer MK
CA Cancer J Clin; 1999; 49(5):264-81. PubMed ID: 11198954
[TBL] [Abstract][Full Text] [Related]
17. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Steuber T; Nurmikko P; Haese A; Pettersson K; Graefen M; Hammerer P; Huland H; Lilja H
J Urol; 2002 Nov; 168(5):1917-22. PubMed ID: 12394676
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
[TBL] [Abstract][Full Text] [Related]
19. Determination of the percentage of free prostate-specific antigen helps to avoid unnecessary biopsies in men with normal rectal examinations and total prostate-specific antigen of 4-10 ng/ml.
Martínez-Piñeiro L; Tabernero A; Contreras T; Madero R; Lozano D; López-Tello J; Alonso-Dorrego JM; Picazo ML; González Gancedo P; Martínez-Piñeiro JA; de La Peña JJ
Eur Urol; 2000 Mar; 37(3):289-96. PubMed ID: 10720854
[TBL] [Abstract][Full Text] [Related]
20. Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic gray zone of total prostate-specific antigen.
Luderer AA; Chen YT; Soriano TF; Kramp WJ; Carlson G; Cuny C; Sharp T; Smith W; Petteway J; Brawer MK
Urology; 1995 Aug; 46(2):187-94. PubMed ID: 7542820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
